The overall beneficial effects of exercise are well studied, but why some people do not respond favourably to exercise is less understood. The National Institutes of Health Common Fund has recently launched the large-scale discovery project 'Molecular Transducers of Physical Activity in Humans' to examine the physiological and molecular (i.e. genetic, epigenetic, lipidomic, metabolomic, proteomic, etc.) responses to exercise training. A nationwide, multicentre clinical trial such as this one also provides a unique opportunity to robustly investigate the non-response to exercise in thousands of individuals that have undergone supervised aerobic-and resistance-based exercise training interventions. The term 'non-responder' is used here to address the lack of a response (to an exercise intervention) in an outcome specified a priori. Cardiorespiratory fitness (V O 2peak ) as an exercise response variable was recently reviewed; thus, this review focuses on metabolic aspects of the non-response to exercise training. Integrated -omics platforms are discussed as an approach to disentangle the complicated relationships between endogenous and exogenous factors that drive the lack of a response to exercise in some individuals. Harnessing the power of combined -omics platforms with deep clinical phenotyping of human study participants will advance the field of exercise metabolism and shift the paradigm, allowing exercise interventions to be targeted at those most likely to benefit and identifying novel approaches to treat those who do not. What is a non-response?From a statistical perspective, a non-response is the lack of a difference between a control and a treatment condition with respect to a specific variable. A physiological non-response, however, is likely driven by genetic code and the mechanisms by which it is transcribed, translated and post-translationally modified. Drug resistance is an archetype of non-response that links physiology with genetics. For example, some individuals are 'rapid' or 'slow' metabolisers of a prescribed drug based solely on their genetic predispositions, and simple DNA tests can now identify these at-risk populations (reviewed in [1]). Combination drug therapy for initial non-response, acquired resistance or adverse response is usually the next course of action; therefore, tailoring treatment to the genetic code is a viable strategy for some diseases and conditions. Response heterogeneity is not unique to pharmaceutical therapies; lifestyle interventions, such as dietary weight loss and exercise, have also been linked to physiological, genetic and epigenetic factors. Differences in energy efficiency are important physiological regulators of body weight and Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00125-017-4461-6) contains a slide of the figure for download, which is available to authorised users. * Lauren M. Sparks